Skip to main content

Table 1 AML patient information

From: Increased methylation upstream of the MEG3 promotor is observed in acute myeloid leukemia patients with better overall survival

Parameter Characteristic Value
General Information Number of patients 45
Mean (range) age in years 48.7 (19–65)
Mean (± SD) white blood cell count (G/l) 45.01 ± 65.95
Mean (range) of blastic cells in the peripheral blood (%) 56 (0–97)
Mean (range) of blastic cells in the bone marrow (%) 65 (20–97)
Mean (± SD) lactate dehydrogenase (U/L) 504.4 ± 344.4
AML subtypes based on WHO classification (n,(%)) AML with recurrent genetic abnormalities t(8;21)(q22;q22);(AML1/ETO) 1 (2.2%)
inv [16](p13;q22) or t(16;16)(p13;q22);(CBFβ/MYH11) 4 (8.9%)
t(9;11); MLLT3-MLL 2 (4.4%)
AML with multilineage dysplasia without antecedent MDS 3 (6.7%)
AML (therapy-related) 0 (0%)
AML (not otherwise categorized; n = 35) AML (minimally differentiated) 4 (8.9%)
AML (without maturation) 8 (17.8%)
AML (with maturation) 13 (28.9%)
Acute myelomonocytic leukemia (AMMoL) 8 (17.8%)
AMMoL with eosinophilia 0 (0.0%)
Acute monocytic leukemia 2 (4.4%)
Acute erythroid leukemia 0 (0.0%)
Acute megakaryoblastic leukemia 0 (0.0%)
Mutations FLT3-ITD/NPM1mut/CEBPAmut 9/3/1
Induction therapy outcome Complete remission after 1st induction 24
Complete remission after 2nd induction 6
Complete remission after 3rd induction 3
Mortality (1st/2nd/3rd induction/consolidation) 5/4/3/0
Post-consolidation treatment Allogenic hematopoietic stem cell transplant 30
Maintenance 3
Risk Favorable risk 7 (15.6%)
Intermediate risk I 10 (22.2%)
Intermediate risk II 8 (17.8%)
Unfavorable risk 20 (44.4%)
  1. NPM1mut mutated nucleophosmin, CEBPAmut CCAAT/enhancer-binding protein alpha, FLT3-ITD internal tandem duplication of FMS-like tyrosine kinase 3